LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 0.99 USD -9.17% Market Closed
Market Cap: 26m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

LAVA Therapeutics NV
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LAVA Therapeutics NV
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Gross Profit
$3.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Gross Profit
$255.4m
CAGR 3-Years
-7%
CAGR 5-Years
13%
CAGR 10-Years
59%
ProQR Therapeutics NV
NASDAQ:PRQR
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Gross Profit
$2m
CAGR 3-Years
-83%
CAGR 5-Years
N/A
CAGR 10-Years
-7%
argenx SE
XBRU:ARGX
Gross Profit
$1.7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Gross Profit
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
26m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.18 USD
Undervaluation 55%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Gross Profit?
Gross Profit
3.3m USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Gross Profit amounts to 3.3m USD.

Back to Top